Amanda Wakefield

发表

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

R. Grossman, S. Powell, Y. Kew, 2017, JAMA oncology.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

M. Baker, J. Orange, W. Wels, 2016, The Journal of clinical investigation.

Autologous HER2 CMV bispecific CAR T cells are safe and demonstrate clinical benefit for glioblastoma in a Phase I trial.

R. Grossman, S. Powell, H. Heslop, 2015, Journal of Immunotherapy for Cancer.

Fibrotic pathways in the dystrophin deficient heart

A. Wakefield, Amanda Wakefield, 2009 .

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

M. Baker, J. Orange, W. Wels, 2019, The Journal of clinical investigation.

Amendment history : Expression of Concern ( July 2019 ) Tandem CAR T cells targeting HER 2 and IL 13 R a 2 mitigate tumor antigen escape

M. Baker, J. Orange, W. Wels, 2019 .

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

M. Baker, J. Orange, W. Wels, 2021, The Journal of clinical investigation.

A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma

J. Orange, W. Wels, A. Pignata, 2015, Journal of Immunotherapy for Cancer.

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients

S. Powell, A. Pignata, M. Chintagumpala, 2015, Journal of Neuro-Oncology.